Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.34 |
| ▸ | KDM5A | P29375 | 5/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 5/20 | 0.34 |
| ▸ | CPB1 | P15086 | 3/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.32 |
| ▸ | KDM4A | O75164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896123 | 0.78 | RAB9A (0.39) | KDM5AKDM5BKDM4CKDM4AALDH1A1 | |
| SCHEMBL2203122 | 0.75 | CPB2 (0.33) | CPB2KDM5AKDM5BCPB1 | |
| SCHEMBL21404585 | 0.74 | CPB2 (0.34) | CPB2KDM5AKDM5BCPB1 | |
| SCHEMBL2198222 | 0.73 | CPB2 (0.32) | CPB2CPB1 | |
| SCHEMBL4891565 | 0.73 | MEN1 (0.47) | MAPTMEN1KMT2A | |
| SCHEMBL27788082 | 0.72 | CPB2 (0.34) | CPB2CPB1ALDH1A1POLBMAPT | |
| SCHEMBL11908082 | 0.71 | KDM5A (0.37) | CPB2KDM5AKDM5BCPB1KDM4C | |
| SCHEMBL1876333 | 0.70 | CPB2 (0.35) | CPB2CPB1 | |
| SCHEMBL584619 | 0.69 | CA12 (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL23320277 | 0.69 | TBXAS1 (0.42) | CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300290-A1 | Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | TRIESELMANN THOMAS | 2008-09-25 | — | — | US | disclosed |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | CPB2 1435/4885KDM5A 3846/4885KDM5B 4228/4885 |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | CPB2 1435/4885KDM5A 3846/4885KDM5B 4228/4885 |
| US-20080300290-A1 | Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments | ADRB1, ADRB3, ADRB2 | CPB2 2153/4885KDM5A 2166/4885KDM5B 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.